PDF(Pubmed)
Abstract：
UNASSIGNED: Hemorrhagic ascites is characterized as red blood cell count greater than 10,000/mm3. In cirrhosis, ascites is an event of decompensation, and associated with poor prognosis. However, significance of hemorrhagic ascites is unclear. We conducted a systematic review and meta-analysis to evaluate the significance of hemorrhagic ascites in cirrhotic patients.
UNASSIGNED: We conducted a systematic search in Embase, MEDLINE, Cochrane Central Register of Controlled Trials, the World Health Organization (WHO) International Clinical Trial Registry, and Web of Science Core Collection to identify studies till March 2021, which, in patients with cirrhosis, compared outcomes amongst those with hemorrhagic ascites to those with non-hemorrhagic ascites. The primary outcome was 3-year mortality, and secondary outcomes were acute kidney injury (AKI), hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP) and portal vein thrombosis (PVT).
UNASSIGNED: Four studies, with 2,058 cirrhosis patients, were included. Among these, 1,488 patients had non-hemorrhagic ascites and 570 had hemorrhagic ascites. We observed no significant differences in AKI (odds ratio (OR) = 2.55; confidence interval (CI): 0.58 - 11.24), HE (OR = 2.52; CI: 0.70 - 9.05), SBP (OR = 1.66; CI: 0.12 - 22.83) and PVT (OR = 0.99; CI: 0.71 - 1.39). Intensive care unit (ICU) stay was significantly higher in patients with hemorrhagic ascites compared to those with non-hemorrhagic ascites (OR = 1.79; CI: 1.37 - 2.36; I2 = 56%). Pooled 3-year mortality was significantly higher in those with hemorrhagic (72.5% (CI: 68.2-76.4%)) when compared to non-hemorrhagic ascites (57.9% (CI: 55.2-60.6%)) (OR = 2.17; CI: 1.71 - 2.74) with low heterogeneity (I2 = 15%).
UNASSIGNED: In patients with cirrhosis, hemorrhagic ascites is a poor prognostic marker, which is associated with increased ICU stay and mortality. Prospective studies are needed to further evaluate significance of hemorrhagic ascites in patients with cirrhosis.
UNASSIGNED: We conducted a systematic search in Embase, MEDLINE, Cochrane Central Register of Controlled Trials, the World Health Organization (WHO) International Clinical Trial Registry, and Web of Science Core Collection to identify studies till March 2021, which, in patients with cirrhosis, compared outcomes amongst those with hemorrhagic ascites to those with non-hemorrhagic ascites. The primary outcome was 3-year mortality, and secondary outcomes were acute kidney injury (AKI), hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP) and portal vein thrombosis (PVT).
UNASSIGNED: Four studies, with 2,058 cirrhosis patients, were included. Among these, 1,488 patients had non-hemorrhagic ascites and 570 had hemorrhagic ascites. We observed no significant differences in AKI (odds ratio (OR) = 2.55; confidence interval (CI): 0.58 - 11.24), HE (OR = 2.52; CI: 0.70 - 9.05), SBP (OR = 1.66; CI: 0.12 - 22.83) and PVT (OR = 0.99; CI: 0.71 - 1.39). Intensive care unit (ICU) stay was significantly higher in patients with hemorrhagic ascites compared to those with non-hemorrhagic ascites (OR = 1.79; CI: 1.37 - 2.36; I2 = 56%). Pooled 3-year mortality was significantly higher in those with hemorrhagic (72.5% (CI: 68.2-76.4%)) when compared to non-hemorrhagic ascites (57.9% (CI: 55.2-60.6%)) (OR = 2.17; CI: 1.71 - 2.74) with low heterogeneity (I2 = 15%).
UNASSIGNED: In patients with cirrhosis, hemorrhagic ascites is a poor prognostic marker, which is associated with increased ICU stay and mortality. Prospective studies are needed to further evaluate significance of hemorrhagic ascites in patients with cirrhosis.
摘要：
未经证实：出血性腹水的特征是红细胞计数大于10,000/mm3。在肝硬化中，腹水是一种代偿失调的事件，并与预后不良有关。然而,出血性腹水的意义尚不清楚。我们进行了系统评价和荟萃分析，以评估肝硬化患者出血性腹水的意义。
UNASSIGNED：我们在Embase进行了系统的搜索，MEDLINE,Cochrane中央控制试验登记册,世界卫生组织（WHO）国际临床试验注册中心，和WebofScience核心合集来确定到2021年3月的研究，在肝硬化患者中，比较出血性腹水患者与非出血性腹水患者的结局。主要结果是3年死亡率，次要结局是急性肾损伤（AKI），肝性脑病(HE),自发性细菌性腹膜炎（SBP）和门静脉血栓形成（PVT）。
未经批准：四项研究，有2058名肝硬化患者，包括在内。其中,1,488例患者有非出血性腹水和570例出血性腹水。我们观察到AKI没有显着差异（优势比（OR）=2.55;置信区间（CI）：0.58-11.24），HE（OR=2.52；CI：0.70-9.05），SBP（OR=1.66；CI：0.12-22.83）和PVT（OR=0.99；CI：0.71-1.39）。出血性腹水患者的重症监护病房（ICU）住院时间明显高于非出血性腹水患者（OR=1.79；CI：1.37-2.36；I2=56％）。与非出血性腹水患者(57.9%(CI:55.2-60.6%))(OR=2.17;CI:1.71-2.74),出血性患者(72.5%(CI:68.2-76.4%)的3年总死亡率显著高于非出血性腹水患者(I2=15%)。
未经证实：肝硬化患者，出血性腹水是一个预后不良的标志物，这与ICU住院时间和死亡率增加有关。需要进行前瞻性研究以进一步评估肝硬化患者出血性腹水的意义。
UNASSIGNED：我们在Embase进行了系统的搜索，MEDLINE,Cochrane中央控制试验登记册,世界卫生组织（WHO）国际临床试验注册中心，和WebofScience核心合集来确定到2021年3月的研究，在肝硬化患者中，比较出血性腹水患者与非出血性腹水患者的结局。主要结果是3年死亡率，次要结局是急性肾损伤（AKI），肝性脑病(HE),自发性细菌性腹膜炎（SBP）和门静脉血栓形成（PVT）。
未经批准：四项研究，有2058名肝硬化患者，包括在内。其中,1,488例患者有非出血性腹水和570例出血性腹水。我们观察到AKI没有显着差异（优势比（OR）=2.55;置信区间（CI）：0.58-11.24），HE（OR=2.52；CI：0.70-9.05），SBP（OR=1.66；CI：0.12-22.83）和PVT（OR=0.99；CI：0.71-1.39）。出血性腹水患者的重症监护病房（ICU）住院时间明显高于非出血性腹水患者（OR=1.79；CI：1.37-2.36；I2=56％）。与非出血性腹水患者(57.9%(CI:55.2-60.6%))(OR=2.17;CI:1.71-2.74),出血性患者(72.5%(CI:68.2-76.4%)的3年总死亡率显著高于非出血性腹水患者(I2=15%)。
未经证实：肝硬化患者，出血性腹水是一个预后不良的标志物，这与ICU住院时间和死亡率增加有关。需要进行前瞻性研究以进一步评估肝硬化患者出血性腹水的意义。
